Equities

Tarsus Pharmaceuticals Inc

TARS:NSQ

Tarsus Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)34.60
  • Today's Change2.05 / 6.30%
  • Shares traded796.70k
  • 1 Year change+103.53%
  • Beta1.0627
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Tarsus Pharmaceuticals Inc increased its cash reserves by 213.91%, or 153.29m. Cash Flow from Investing totalled 140.60m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 117.49m for operations while cash generated from financing totalled 130.18m.
Cash flow per share-4.35
Price/Cash flow per share--
Book value per share6.63
Tangible book value per share6.54
More ▼

Balance sheet in USDView more

Tarsus Pharmaceuticals Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio7.03
Quick ratio6.99
Total debt/total equity0.2838
Total debt/total capital0.221
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.